Clinical Trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

Purpose is to determine if “MEDI8897” will prevent medically attended Respiratory syncytial virus (RSV) in healthy infants entering their first RSV season.


Principal Investigator Dynio Honrubia, MD
Sponsor MedImmune LLC
Type of Trial Interventional